Breaking News Instant updates and real-time market news.

PODD

Insulet

$105.07

-0.89 (-0.84%)

, NVO

Novo Nordisk

$46.56

-0.56 (-1.19%)

05:16
10/02/18
10/02
05:16
10/02/18
05:16

Insulet says Omipod now available for use in Europe with Fiasp

Insulet (PODD) announced that Novo Nordisk's (NVO) Fiasp has been tested and found safe for use in Insulet's Omnipod System in Europe. Fiasp is a new-generation, ultra fast-acting insulin developed by Novo Nordisk that enters the bloodstream two times faster, compared to NovoRapid, so it more closely matches a healthy body's insulin response to a meal, thereby improving glycemic control. Insulet will showcase its Omnipod System during the European Association for the Study of Diabetes annual meeting at the Messe Berlin Exhibition Halls in Berlin, Germany taking place 1st October to 5th October 2018.

PODD

Insulet

$105.07

-0.89 (-0.84%)

NVO

Novo Nordisk

$46.56

-0.56 (-1.19%)

  • 01

    Nov

  • 27

    Nov

PODD Insulet
$105.07

-0.89 (-0.84%)

07/10/18
BMOC
07/10/18
NO CHANGE
Target $115
BMOC
Outperform
Insulet price target raised to $115 from $100 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Insulet to $115 while also adding the company to her Top Picks list as part of her broader Medical Technology: Mid-year View research note. The analyst notes that the company is "on the right side of a secular trend towards better diabetes management, with a full product pipeline, improved reimbursement, and marching rapidly towards cash flow break-even". Wuensch also kept her Outperform rating on Insulet.
08/03/18
PIPR
08/03/18
NO CHANGE
Target $106
PIPR
Overweight
Insulet pullback on Q2 results should be short-lived, says Piper Jaffray
Insulet last night reported Q2 results below expectations and lowered guidance based on inventory issues internationally, whereby the prior distributor both returned goods and had plenty of inventory in the channel already, Piper Jaffray analyst JP McKim tells investors in a research note. The analyst says that while the news is disappointing, he's been fielding daily investor calls on the subject since late June, so this is not a total shock to the investment community. He believes management on the earnings call handled the issue very well and instilled confidence that it is under control. McKim suspects any share pullback will be short-lived and keeps an Overweight rating on Insulet with a $106 price target.
09/05/18
OPCO
09/05/18
NO CHANGE
Target $54
OPCO
Outperform
Tandem Diabetes price target raised to $54 from $38 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes (TNDM) to $54 from $38 on updated market estimates. The analyst notes that Medtronic's (MDT) recently reported Q1 diabetes results combined with the Q2 performances from Tandem as well as Insulet (PODD) suggests a strong underlying U.S. insulin pump market. Lichtman is raising his U.S. insulin market growth outlook from high-single digits to low-double digits in 2019/2020. He believes Tandem is well suited to capture the benefits of this acceleration given its pipeline. Lichtman reiterates an Outperform rating on Tandem's shares.
09/11/18
LEER
09/11/18
NO CHANGE
Target $130
LEER
Outperform
Insulet price target raised to $130 from $100 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Insulet to $130 from $100 after the company announced that Patrick Sullivan would be stepping down as CEO at the end of this year, passing the baton to current COO Shacey Petrovic on January 1, 2019. The analyst believes this transition indicates that Insulet fundamentals are stronger than ever. In conjunction with the announcement, the company also reiterated full year 2018 sales guidance of $547M-$562M, she adds. Antalffy reiterates an Outperform rating on the shares.
NVO Novo Nordisk
$46.56

-0.56 (-1.19%)

06/01/18
ROTH
06/01/18
NO CHANGE
Target $400
ROTH
Buy
Roth Capital ups Madrigal price target to $400, examines possible M&A scenarios
Roth Capital analyst Yasmeen Rahimi noted that Madrigal Pharmaceuticals' (MDGL) "impressive" NASH resolution results published yesterday resulted in the stock's value being pushed up to make it the highest among "purely NASH" companies. Among large pharma companies, Rahimi believes those with the strongest metabolic franchises, large R&D teams, and sales forces focused on endocrinologists, gastroenterologists, and hepatologists likely have eyes on NASH assets, listing Merck (MRK), AstraZeneca (AZN), Eli Lilly (LLY) and Novo Nordisk (NVO) as examples. The historical acquisition price for NASH assets ranges from $200M to $1.7B, but Rahimi argues that Madrigal "can set the highest NASH price tag yet," estimating a potential takeout valuation of $5.6B. Rahimi raised her price target on Madrigal shares to $400 from $210 and keeps a Buy rating on the stock.
07/02/18
BERN
07/02/18
UPGRADE
BERN
Outperform
Novo Nordisk upgraded to Outperform from Market Perform at Bernstein
07/19/18
BMOC
07/19/18
NO CHANGE
Target $80
BMOC
Market Perform
Eli Lilly to have a 'good Q2' on beats from launch franchises, says BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $80 from $78 ahead of its Q2 earnings, saying the company will have a "good" quarter on "beats from its launch franchises Trulicity, Jardiance, and Basaglar". The analyst also keeps his Market Perform rating, adding that while the the pipeline potential of its Galcanezumab and Tanezumab drugs is promising, he believes investors are underappreciating the headwinds around its diabetes program. He see higher risks of an increased biosimilar erosion for Humalog from Sanofi's (SNY) Admelog, and Trulicity competitive pressure from Novo's (NVO) Ozempic in 2019.
09/19/18
NEED
09/19/18
NO CHANGE
Target $29
NEED
Zealand Pharma price target raised to $29 from $26 at Needham
Needham analyst Alan Carr raised his price target on Zealand Pharma (ZEAL) to $29 and kept his Buy rating after its announced Phase 3 trial results of dasiglucagon in Acute Severe Hypoglycemia. The analyst notes that the trial met its primary median time endpoint for glucose recovery, adding that the rapid response is comparable to the currently marketed Glucagen made by Novo Nordisk (NVO). With phase 3 trial expected to be launched this month, Carr anticipates Zealand's potential commercialization of dasiglucagon to come in 2020 and for peak sales to reach $360M in 2030.

TODAY'S FREE FLY STORIES

OSBC

Old Second Bancorp

$13.89

0.09 (0.65%)

17:03
01/23/19
01/23
17:03
01/23/19
17:03
Earnings
Old Second Bancorp reports Q4 EPS 29c, consensus 30c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQBK

Equity Bancshares

$34.52

-0.27 (-0.78%)

17:00
01/23/19
01/23
17:00
01/23/19
17:00
Earnings
Equity Bancshares reports Q4 EPS 62c, consensus 74c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SLM

Sallie Mae

$9.49

0.1 (1.07%)

16:45
01/23/19
01/23
16:45
01/23/19
16:45
Hot Stocks
Sallie Mae jumps after announcing new dividend and repurchase programs »

"Last year, nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

LONE

Lonestar Resources

$4.68

-0.02 (-0.43%)

16:44
01/23/19
01/23
16:44
01/23/19
16:44
Hot Stocks
B. Riley takes 9.9% passive stake in Lonestar Resources »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WVE

Wave Life Sciences

$41.71

0.91 (2.23%)

16:44
01/23/19
01/23
16:44
01/23/19
16:44
Hot Stocks
Breaking Hot Stocks news story on Wave Life Sciences »

Wave Life Sciences down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TST

TheStreet

$2.03

-0.05 (-2.40%)

16:43
01/23/19
01/23
16:43
01/23/19
16:43
Hot Stocks
B. Riley takes 7.3% passive stake in TheStreet »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$35.79

-0.49 (-1.35%)

, EADSY

Airbus

$0.00

(0.00%)

16:40
01/23/19
01/23
16:40
01/23/19
16:40
Hot Stocks
Air Lease announces lease pacts with SAS for Airbus A321-200neo jets »

Air Lease (AL) announced…

AL

Air Lease

$35.79

-0.49 (-1.35%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

BA

Boeing

$358.81

0.9 (0.25%)

16:39
01/23/19
01/23
16:39
01/23/19
16:39
Hot Stocks
Boeing completes first test flight of autonomous passenger air vehicle »

Boeing said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 28

    May

UVSP

Univest

$22.87

0.18 (0.79%)

16:39
01/23/19
01/23
16:39
01/23/19
16:39
Earnings
Univest reports Q4 EPS 63c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

16:37
01/23/19
01/23
16:37
01/23/19
16:37
General news
API crude inventories for week of January 18 »

API reports that crude…

LOB

Live Oak Bancshares

$15.40

-0.07 (-0.45%)

16:37
01/23/19
01/23
16:37
01/23/19
16:37
Earnings
Live Oak Bancshares reports Q4 EPS 26c, consensus 12c »

Reports Q4 tangible book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

16:36
01/23/19
01/23
16:36
01/23/19
16:36
Hot Stocks
Breaking Hot Stocks news story on Xilinx »

Xilinx up 8% to $96.80…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Feb

OHRP

Ohr Pharmaceutical

$0.12

-0.0035 (-2.79%)

16:36
01/23/19
01/23
16:36
01/23/19
16:36
Hot Stocks
Ohr Pharmaceutical announces one-for-twenty reverse stock split »

Ohr Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRMK

Trustmark

$30.50

0.22 (0.73%)

16:36
01/23/19
01/23
16:36
01/23/19
16:36
Earnings
Trustmark reports Q4 EPS 55c, consensus 54c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

CNS

Cohen & Steers

$36.95

0.24 (0.65%)

16:35
01/23/19
01/23
16:35
01/23/19
16:35
Earnings
Cohen & Steers reports Q4 adjusted EPS 56c, consensus 59c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

ADXS

Advaxis

$0.32

-0.0283 (-8.16%)

16:35
01/23/19
01/23
16:35
01/23/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Advaxis 

Advaxis trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVLR

Avalara

$39.72

-0.38 (-0.95%)

16:34
01/23/19
01/23
16:34
01/23/19
16:34
Hot Stocks
Avalara expands into alcoholic beverage compliance through acquisition »

Avalara announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 25

    Feb

  • 03

    Mar

SLM

Sallie Mae

$9.49

0.1 (1.07%)

16:34
01/23/19
01/23
16:34
01/23/19
16:34
Earnings
Sallie Mae sees FY19 EPS $1.22-$1.26, consensus $1.21 »

Sees FY19 private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

BXS

BancorpSouth

$28.54

-0.13 (-0.45%)

16:33
01/23/19
01/23
16:33
01/23/19
16:33
Earnings
BancorpSouth reports Q4 EPS 47c, consensus 55c »

"As we look…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SLM

Sallie Mae

$9.49

0.1 (1.07%)

16:32
01/23/19
01/23
16:32
01/23/19
16:32
Earnings
Sallie Mae reports Q4 adjusted EPS 33c, consensus 27c »

Reports Q4 revenue $383M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

CATY

Cathay General

$37.28

0.12 (0.32%)

16:32
01/23/19
01/23
16:32
01/23/19
16:32
Earnings
Cathay General reports Q4 EPS 80c, consensus 80c »

Return on average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 12

    Mar

CHRA

Charah Solutions

$6.97

0.19 (2.80%)

16:32
01/23/19
01/23
16:32
01/23/19
16:32
Hot Stocks
Charah Solutions names Scott Sewell president, CEO »

Charah Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRA

Charah Solutions

$6.97

0.19 (2.80%)

16:31
01/23/19
01/23
16:31
01/23/19
16:31
Hot Stocks
Charah Solutions CEO Charles Price to step down, Scott Sewell to succeed »

Charah Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$132.89

10.55 (8.62%)

, UTX

United Technologies

$117.08

5.85 (5.26%)

16:31
01/23/19
01/23
16:31
01/23/19
16:31
On The Fly
Fly Intel: Wall Street's top stories for Wednesday »

Stocks opened higher…

IBM

IBM

$132.89

10.55 (8.62%)

UTX

United Technologies

$117.08

5.85 (5.26%)

PG

Procter & Gamble

$94.87

4.37 (4.83%)

CMCSA

Comcast

$36.87

1.71 (4.86%)

CMCSK

Comcast

$0.00

(0.00%)

VZ

Verizon

$57.77

0.78 (1.37%)

ORCL

Oracle

$49.25

0.29 (0.59%)

VIPS

Vipshop

$7.08

0.6 (9.26%)

ARAY

Accuray

$4.41

0.44 (11.08%)

WAT

Waters

$229.46

25.94 (12.75%)

TSLA

Tesla

$287.41

-11.39 (-3.81%)

COF

Capital One

$78.19

-5.19 (-6.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 11

    Feb

  • 18

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

BGG

Briggs & Stratton

$13.73

-0.46 (-3.24%)

16:31
01/23/19
01/23
16:31
01/23/19
16:31
Earnings
Briggs & Stratton cuts FY19 EPS view to $1.10-$1.30 from $1.40-$1.60 »

Consensus $1.44. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.